Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11490011 | 0.85 | CYP3A4 (0.44) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL657891 | 0.84 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL780471 | 0.84 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL6882694 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL14966499 | 0.82 | MAPT (0.50) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL5702149 | 0.82 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TSHRGLAMAPT | |
| SCHEMBL5702191 | 0.82 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TSHRGLAMEN1 | |
| SCHEMBL380050 | 0.81 | ALDH1A1 (0.76) | ALDH1A1CYP3A4TSHRL3MBTL1GLA | |
| Hydrochloric Acid SCHEMBL10801383 | 0.81 | ALDH1A1 (0.48) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL11779571 | 0.80 | ALDH1A1 (0.64) | ALDH1A1CYP3A4TSHRTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017153952-A1 | 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-14 | — | — | WO | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150080426-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | AUSPEX PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8487100-B2 | Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | STC.UNM (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | STC. UNM (US) | 2011-04-21 | — | — | US | disclosed |
| US-7875721-B2 | Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause | STC.UNM (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | ARROWHEAD CENTER, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2007019180-A2 | COMPOUNDS FOR BINDING TO ERALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-0356931-B1 | Anthrapyridone compounds having vinylsulfone type fiber reactive group through triazinyl bridging group | SUMITOMO CHEMICAL CO (JP) | 1995-01-18 | — | — | EP | disclosed |
| EP-0276686-B1 | ANTHRAQUINONE COMPOUND AND DYEING OR PRINTING METHOD USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-09-04 | — | — | EP | disclosed |
| US-4977261-A | FIBER-REACTIVE DYES | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 1990-12-11 | — | — | US | disclosed |
| US-4975094-A | Anthrapyridone compounds having vinylsulfone type fiber reactive group through triazinyl bridging group | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ALDH1A1 3674/4885CYP3A4 3280/4885TSHR 1435/4885 |
| US-20150080426-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | SLC18A2, ACAT2, SLC6A2 | ALDH1A1 695/4885CYP3A4 1377/4885TSHR 3869/4885 |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | GPER1, ESR2, ESRRG | ALDH1A1 2014/4885CYP3A4 835/4885TSHR 216/4885 |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | GPER1, ESR2, ESRRG | ALDH1A1 1647/4885CYP3A4 746/4885TSHR 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.